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Purified &N-acetylglucosamimde /?( I-4)galactosyltransferase and partially purified /Lgalactoside CY(~-6)- 
slalyltransferase were used to elongate and terminate glycan chains of agalacto-ovalbumin and endo-D-N- 
acetylglucosaminidase H-treated yeast invertase in vitro. In the presence of both transferases, 0.1 mol sialic 
acid was incorporated per mol agalacto-ovalbumin within 24 h. Evidence is presented to show that purifica- 
tion of the galactosylated intermediate increases the efficiency of sialylation. Incorporation of sialic acid 
mto endo-~-~-acetylglucosaminidase H-treated oligomannose glycoproteins may be useful for in vivo stabi- 
lization of these glycoproteins by preventing uptake in liver or reticuloendothelial cells. 
U~igomannose glycan 0 valbumin Endo-p-N-acetylglucosaminidase H2 Jnvertase 
(Saccharomyces cerevisiae) Glycosylation 
1. INTRODUCTION 
Optimum conditions for in vitro synthesis of 
biopolymers are difficult to achieve. This holds for 
template-based biosynthetic reactions such as 
replication, transcription and translation (review 
[l]) as well as for non-template based mechanisms 
of glycan biosynthesis (review [2]). Although pro- 
gress has been made in recent years in under- 
standing Golgi-associated glycosylation [3,4], 
much remains to be learned about the molecular 
mechanisms of glycan biosynthesis in vivo. Cur- 
rent evidence favors a model of Golgi-associated 
glycosylation in which each step in chain elonga- 
tion and termination of complex glycans takes 
place in different compartments. This is in accor- 
~bbrev~at~ons~ NeuAc, ~-acetylneuraminic acid; gal, 
galactose; GIcNAc, N-acetyiglucosamine; UDP, uridine 
diphosphate; CMP, cytidine monophosphate; Gal-T, 
galactosyltransferase; Sialyl-T, sialyltransferase; Endo 
H, endo-P-N-acetylglucosaminidase H 
dance with the ‘assembly-line’ model for glycan 
biosynthesis as opposed to the template-based pro- 
cess of protein and nucleic acid biosynthesis [3]. 
Single glycosylation steps have been carried out 
in vitro using crude or purified glycosyltransferases 
in soluble phase [2] or solid phase [5,6] for many 
years. In vitro chain elongation and termination 
(i.e. the incorporation of terminal sialic acid), 
however, has not been reported; such an in vitro 
glycosation system may be useful for at least two 
potential applications. First, mammalian glyco- 
proteins expressed in yeasts by a recombinant 
DNA approach ([7,8] and references cited therein) 
may not be suitable for in vivo application since 
they are likely to be substituted by mannans; 
second, immunotoxins containing ricin A chains 
(an oligomannosidic g~ycoprotein) injected into the 
circulation of laboratory animals had a very short 
half-life due to rapid removal by the reticulo- 
endothelial system [9]. 
As a first attempt toward the objective of in- 
troducing sialic acid into yeast glycoproteins, we 
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investigated chain elongation and termination in mCi/mmol) and 75 PU Gal-T were incubated in a 
vitro by use of purified and well characterized final volume of 100 pl at pH 7.35 for 15 min at 
glycosyltransferases. An incubation system was 37°C. The reaction was stopped by the addition of 
devised which brought about Gal-T-dependent in- approx. 1 ml phosphotungstic acid in 2 N HCI, the 
corporation of sialic acid into agalacto-ovalbumin precipitate filtered over glass fiber filters (What- 
and was then applied to Endo H-treated yeast in- man GFA), washed with cold ethanol, dried and 
vertase by the following sequence of enzymatic counted in a toluene-based liquid scintillation 
modifications: counting system at an efficiency of 45%. 
Endo H 
1. (Oligomannose)-invertase- 2.3. Standard assay of Sialyl-T 
(GlcNAc)-invertase 
2. (GlcNAc)-invertase Gal% (Gal-GlcNAc)- 
invertase 
3. (Gal-GlcNAc)-invertase Sialyl-T, tNeuAc_ 
Gal-GlcNAc)-invertase 
2. MATERIALS AND METHODS 
10 pmol Na cacodylate, 0.2 mg asialofetuin 
prepared by mild acid hydrolysis [16], 0.2 mg 
bovine serum albumin, 0.1 /cm01 CMP-[3H]NeuAc 
(0.9 mCi/mmol) and 24 mU Sialyl-T were in- 
cubated in a final volume of 55~1 at pH 6.8 for 120 
min at 37°C. The incubation was stopped by addi- 
tion of approx. 1 ml phosphotungstic acid (5%, 
w/v) and trichloroacetic acid (15%, w/v) in HlO; 
the precipitate was treated and assessed for radio- 
activity as indicated above. 
2.1. biological material 2.4. Incubation conditions for Gun-T-de~e~denf 
Human milk was obtained through the help of 
La Leche League; bovine colostrum was obtained 
from farms near Berne. Ovalbumin (grade 5) was 
from Sigma. a-Lactalbumin was purified from 
human milk according to [lo]. Fetuin and sialidase 
(Vibrio cholerae, 20 U/mg) were from Calbiochem. 
Endo H was purified from 6 1 of a cell-free filtrate 
from a stationary culture of Stre~tomyces ~~~~atus 
essentially according to [ll]. Gal-T (EC 2.4.1.22) 
was purified from human milk by two sequential 
affinity chromatography steps on columns of 
GlcNAc-Sepharose and Lu-lactalbumin-Sepharose 
[12] and Sialyl-T (EC not specified) was partially 
purified from bovine colostrum on CDP-ethanol- 
amine-Sepharose [131. Invertase obtained from 
Boehringer was further purified by ion-exchange 
chromatography on a 20 ml DEAE-Sepharose col- 
umn equilibrated in 0.01 M Na phosphate, pH 6.5, 
and subjected to a linear gradient of O-O.2 M 
NaCl. Fractions containing activity were pooled, 
dialyzed against 0.01 M Na acetate, pH 5.3, and 
stored at -2O’C. Periodate oxidation of oval- 
bumin was carried out according to Spiro [14] to 
remove terminal galactose residues [ 151. 
siulyfation of aga~a~to-ova~bumin 
The incubation contained in a final volume of 2 
ml: 10 ymol Na cacodylate, 2 ,umol MnC12, 40 
nmol UDPGal, 1 mg agalacto-ovalbumin, 2.5 
nmol CMP-[3H]NeuAc (7.15 mCi/mmol), 0.13 
mU purified Gal-T and 70 mU partially purified 
Sialyl-T. 
2.5. Deglycosylation of invertase 
Purified invertase (22 mg) was incubated with 10 
mU Endo H in 8 ml of 0.1 M Na citrate, pH 5.3, 
containing 4% (v/v) thiophene, tetrahydro-1, l-di- 
oxide (sulfolane, Fluka) and a few drops of toluene 
at 37°C for 48 h. The incubation mixture was 
brought to 1% Triton X-100, boiled for 10 min 
and dialyzed against 0.005 M Tris-HCl, pH 7.0, 
containing 1% Triton X-100. The extent of degly- 
cosylation was assessed by the increase in elec- 
trophoretic mobility of invertase according to [ 171. 
Electrophoresis and fluorography were carried out 
according to Maniatis et al. [ 181. 
3. RESULTS 
2.2. Standard assay for Gal-T 
10 pmol Na cacodylate, 1 pmol M&12, 1 mg 
native ovalbumin, 20 nmol UDP-[3H]galactose (5 
3.1. Sialylation of agalacto-ovalbumin 
Native ovalbumin is known to contain hybrid- 
type glycans terminated by Gal&( I-4)GlcNAg 
(l-2/4)R and GlcNAc@(l-2/4)R branches. Thus, 
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ovalbumin exposes acceptor sites for both Sialyl-T 
and Gal-T, respectively [ 151. Preliminary assays 
using Sialyl-T and Gal-T with native ovalbumin as 
acceptor substrate confirmed this assumption (not 
shown). Since we aimed at finding incubation con- 
ditions which would allow the demonstration of 
Gal-T-dependent sialylation of terminal N-acetyl- 
glucosamine residues only, we subjected native 
ovalbumin to periodate oxidation to produce aga- 
lacto-ovalbumin [ 151. By comparison with native 
ovalbumin, periodate-treated ovalbumin preserved 
62% of its original acceptor activity for Gal-T, 
whereas acceptor activity for Sialyl-T was com- 
pletely abolished (not shown). Next, we studied 
glycosylation of agalacto-ovalbumin in a system in 
which both Gal-T and Sialyl-T and their respective 
donor substrates were present. Up to 2.09 nmol 
sialic acid per mg agalacto-ovalbumin were incor- 
porated within 24 h during which sialylation was 
linear; this corresponded to an efficiency of 0.1 
mol sialic acid per mol ovalbumin. In control in- 
cubations in which Gal-T or agalacto-ovalbumin 
was omitted, small but similar amounts of sialic 
acid were incorporated into acid-precipitable ma- 
terial which probably represented endogenous ac- 
ceptor present in the partially purified Sialyl-T 
preparation. Treatment of the sialylated 
ovalbumin with V. cholerae sialidase for 3 h at 
37°C completely removed the radiolabel. From 
these data we drew the conclusion that glycosyla- 
tion in soluble phase by combining sequentially 
acting glycosyltransferases is possible but relatively 
slow since maximum incorporation was achieved 
only after 24 h. We then tested a system in which 
galactosylated ovalbumin was first purified by 
separating unreacted UDP-galactose from UDP 
generated by the reaction on a Bio-Gel P2 column, 
removing Gal-T by affinity chromatography on CYY- 
lactalbumin-Sepharose [ 191 and desalting on a PD 
10R column with subsequent concentration of the 
purified galactosylated product in a MiniconK 
device. After this stepwise procedure, incorpora- 
tion of sialic acid into galactosylated ovalbumin 
was approx. 2.5times higher than in the combined 
assay with the same overall incubation time (table 
1). 
3.2. Sialylation of Endo H-treated invertase 
To investigate whether an analogous glycosyla- 
tion procedure could be used to incorporate sialic 
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Table 1 
Stepwise vs combined galactosylation and sialylation of 
agalacto-ovalbumin 
Incubation cpm[3H]NeuAc pmol” 
(3H]NeuAc 
Stepwise incubationb 837 116 
Control without 
Gal-T 32 4 
Combined incubation‘ 358 50 
a Conversion of cpm to pmol was based on 45% count- 
ing efficiency and a specific activity of 7.15 mCi/mmol 
b Galactosyiation for 60 min at 37’C followed by 
purification of galactosylated ovalbumin, then sialyta- 
tion for 60 min at 37°C. incorporation of [3H]NeuAc 
into acid-precipitable material is measured 
’ Transfer of galactose and sialic acid took place in a 
combined incubation for 120 min at 37°C 
acid to the core N-acetylglucosamine of Asn-linked 
glycans, yeast invertase was treated with Endo H 
and subsequently with Gal-T and Sialyl-T. First, 
Endo H treatment of invettase produced an en- 
zyme form of approx. 65 kDa as judged by elec- 
trophoretic mobility in SDS-PAGE (not shown) 
corresponding to the unraveling of 9 core N- 
acetylglucosamine acceptor sites per mol 
deglycosyiated invertase ]17]; this enzyme form 
proved to be an excellent acceptor for Gal-T. Table 
2 shows the comparative incorporation of 
radiolabeled galactose into native and Endo H- 
treated invertase. Incorporation of 2.3 nmol galac- 
tose into Endo H-treated invertase corresponds to 
a galactosylation of 26% of available acceptor 
sites. A combined incubation containing both Gal- 
Table 2 
Glycosylation of Endo H-treated invertase 
Invertase 
Native Treated 
nmol[‘H]Gal incorporated in 
45 min at 37°C per 1OOpg 
acceptor protein 
Net incorporation of [3H]NeuAc, 
nmol in 19 h per 100,~g 
acceptor protein (after subtrac- 
tion of label incorporated in 
endogenous acceptors) 
0.01 2.300 
0 0.385 
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T and Sialyl-T led to the incorporation of sialic 
acid into Endo H-treated invertase (table 2), 
amounting to approx. 17% of the galactosylated 
acceptor sites. Control incubations in the absence 
of Gal-T, and Sialyl-T, UDPGal or invertase all 
produced similar but low amounts of labeled 
material due to endogenous acceptor in the Sialyl- 
T preparations. Subsequent reatment of sialylated 
invertase with V. cholerue sialidase removed all the 
incorporated label by overnight incubation at 37°C 
(not shown). 
4. DISCUSSION 
Our data demonstrate in vitro chain elongation 
and termination of ovalbumin in an assay system 
in which two sequentially acting glycosyltransfer- 
ases with defined specificities were combined: 
Gal-T is known to catalyze the formation of a 
galactose ,&( I-4)GlcNAc-R linkage, a specificity 
which has been confirmed for the enzyme prepara- 
tion used in this study [ZO]. Sialyl-T as purified 
according to our procedure was shown to catalyze 
the formation a NeuAm(2-6)Gal linkage [ 131. The 
specificities of purified glycosyltransferases in 
forming defined glycosidic bonds is considered to 
be rigorous and have been used to tag specifically 
terminal glycosyl residues on glycoproteins [21]. 
Therefore, we assume that the product formed by 
the action of the two glycosyltransferases represents 
authentic NeuAcu$2-@Gal& I-4)GlcNAc-R. 
The conditions for combined Gal-T and Sialyl-T 
incubation as presented here to elongate and ter- 
minate glycan chains are far from being optimized. 
Several problems need further research such as: do 
the increasing concentrations of UDP or CMP 
generated by the action of the respective glycosyl- 
transferase inhibit the reactions? Sialyl-T is believed 
to require additional binding sites for optimum ac- 
tivity [22] which are not present on truncated N- 
glycans; is it possible to circumvent this potential 
drawback by increasing the enzyme concentration 
or by stabilizing the enzymes on solid supports? To 
which extent is the biological activity of the treated 
glycoprotein affected by these enzymatic modifica- 
tions? 
In summary, a combined incubation system in- 
volving Gal-T and Sialyl-T has been shown to 
elongate and terminate peripheral glycan chains in 
the case of agalacto-ovalbumin and, albeit at low 
efficiency, of core N-glycans in the case of Endo 
H-treated yeast invertase. This approach represents 
the only possibility reported so far to incorporate 
sialic acid into glycoproteins of the oligomannose 
type. It may thus pave a way to a successful in vivo 
application of immunotoxins or of mammalian 
glycoproteins expressed in yeasts by recombinant 
DNA by increasing their half-life times in circula- 
tion. 
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